Vistagen Therapeutics, Inc.
About Vistagen Therapeutics, Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- -$227.0K
- Net income
- -$51.4M
- Total assets
- $84.3M
- Market cap
- $21.5M
- Operating margin
- -11517.1%
- Net margin
- -10579.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $486.0K
- Operating expenses
- $56.5M
- Operating income
- -$56.0M
- Income tax
- $7.0K
- Net income
- -$51.4M
- EPS (basic)
- $-1.67
- EPS (diluted)
- $-1.67
Balance sheet
- Total assets
- $84.3M
- Current assets
- $82.1M
- Total liabilities
- $14.0M
- Current liabilities
- $12.6M
- Shareholders’ equity
- $70.4M
Cash flow
- Operating cash flow
- -$42.1M
- Investing cash flow
- -$13.1M
- Financing cash flow
- $3.2M
- Net cash flow
- -$52.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $21.5M
- EPS (diluted)
- $-1.67
- Shares outstanding
- 39.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 1, 2009
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $51.4M in FY2023.
- Revenue declined 55% from FY2021 to FY2025.
- Trading 89% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vistagen Therapeutics, Inc..
Write a review
News about Vistagen Therapeutics, Inc.
News & sentiment via Polygon.io
